Business
Notice of Results and Investor Webinar
Notice of Results and Investor Webinar.
About this update from Valirx Plc
[{"type":"text","content":"\n\nValiRx PLC\n(\"ValiRx\" or the \"Company\")\nNotice of Results and Investor Webinar\nLondon, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, will be announcing its audited results for the year ended 31 December 2022 on Monday 5 June 2023.\nA presentation to shareholders and Q&A sessions will be held at the Company's laboratory site in Nottingham on Wednesday, 14 June 2023. \nShareholders are invited to register for a place to attend by emailing the CEO on the details provided below; however, as capacity is limited, registration will be assigned to be either physical or virtual, with virtual attendees provided a link to watch the event via webinar. The webinar will be available to view on demand through our website after the event.\nThe Directors of the Company take responsibility for this announcement.\n \nFor more information, please contact:\n \n\n\n\nValiRx plc\n \nDr Suzanne Dilly, CEO\n \n \n\n\nTel: +44 (0) 2476 796496\nwww.valirx.com\[email protected]\n \n\n\n\n\nV Formation (Public Relations)\n \nLucy Wharton - Senior PR Executive\nSue Carr - Director\n \n\n\n+44 (0) 115 787 0206\nwww.vformation.biz\n \[email protected]\[email protected]\n\n\n\n\nCairn Financial Advisers LLP (Nominated Adviser)\n \nLiam Murray/Jo Turner/Ludovico Lazzaretti\n \n\n\nTel: +44 (0) 20 7213 0880\n\n\n\n\nCenkos Securities plc (Joint Broker)\n \nDale Bellis/Michael Johnson (Sales)\n \nCallum Davidson/Giles Balleny (Corporate Finance)\n \n\n\nTel: +44 (0) 20 7397 8900\n\n\n\n\nTurner Pope Investments (Joint Broker)\nJames Pope / Andy Thacker \n\n\nTel: +44 (0) 20 3657 0050\n \n\n\n\n \nNotes for Editors\nAbout ValiRx\nValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.\nValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.\nUsing its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of develo...